Neuromyelitis optica spectrum disorder after BIBP COVID-19 vaccine: A case report

Neuroimmunology Reports Pub Date : 2023-01-01 DOI:10.1016/j.nerep.2023.100174

Cristiam Gutierrez , Sandro Rodríguez , Miguel Trillo , Alfredo Vásquez , Wilfor Aguirre-Quispe

{"title":"Neuromyelitis optica spectrum disorder after BIBP COVID-19 vaccine: A case report","authors":"Cristiam Gutierrez , Sandro Rodríguez , Miguel Trillo , Alfredo Vásquez , Wilfor Aguirre-Quispe","doi":"10.1016/j.nerep.2023.100174","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>With the COVID-19 vaccine now available, there have been occasional reports of post-vaccination neurological complications.</p></div><div><h3>Case presentation</h3><p>In this report, we present a case of neuromyelitis optica spectrum disorder (NMOSD) that developed one month after the patient received the second dose of BIBP COVID-19 vaccine (SARS-CoV-2-Vaccine [Vero Cell] Inactivated). The patient presented with itching, numbness in the hand and right side of the face, as well as nausea, vomiting, and hiccups. Brain MRI revelead lesions in the area postrema, medulla, and bilateral hypothalamus, which are typical of NMOSD. Serum antibodies to anti-AQP4 and anti-MOG were negative.</p></div><div><h3>Conclusions</h3><p>The pathogenesis of NMOSD development after vaccination is still unknown. NMOSD is generally aggressive and disabling, it is important for the neurologist to be attentive to the highly variable clinical presentation after COVID-19 vaccination for early diagnosis and effective treatment.</p></div>","PeriodicalId":100950,"journal":{"name":"Neuroimmunology Reports","volume":"3 ","pages":"Article 100174"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroimmunology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667257X23000128","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

Abstract

Background

With the COVID-19 vaccine now available, there have been occasional reports of post-vaccination neurological complications.

Case presentation

In this report, we present a case of neuromyelitis optica spectrum disorder (NMOSD) that developed one month after the patient received the second dose of BIBP COVID-19 vaccine (SARS-CoV-2-Vaccine [Vero Cell] Inactivated). The patient presented with itching, numbness in the hand and right side of the face, as well as nausea, vomiting, and hiccups. Brain MRI revelead lesions in the area postrema, medulla, and bilateral hypothalamus, which are typical of NMOSD. Serum antibodies to anti-AQP4 and anti-MOG were negative.

Conclusions

The pathogenesis of NMOSD development after vaccination is still unknown. NMOSD is generally aggressive and disabling, it is important for the neurologist to be attentive to the highly variable clinical presentation after COVID-19 vaccination for early diagnosis and effective treatment.

查看原文本刊更多论文

BIBP新冠肺炎疫苗接种后视神经脊髓炎谱系障碍1例报告

背景随着新冠肺炎疫苗的上市，偶尔会有接种后神经并发症的报告。病例介绍在本报告中，我们介绍了一例视神经脊髓炎谱系障碍（NMOSD）病例，该病例是在患者接种第二剂BIBP新冠肺炎疫苗（SARS-CoV-2疫苗[Vero细胞]灭活）一个月后发生的。患者表现为手部和右侧面部瘙痒、麻木、恶心、呕吐和打嗝。脑MRI显示脊髓后区、髓质和双侧下丘脑的病变，是典型的NMOSD。血清抗AQP4和抗MOG抗体均为阴性。结论接种疫苗后NMOSD的发病机制尚不清楚。NMOSD通常具有攻击性和致残性，对于神经学家来说，在接种新冠肺炎疫苗后关注高度可变的临床表现对于早期诊断和有效治疗很重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neuroimmunology Reports

自引率

0.00%

发文量